At the news
? NEUTRALIMPACT 3/10 S-4 filed Nov 3, 2026 at 17:02 ET
ADC Therapeutics SA filed a preliminary S-4 registration statement to reincorporate from Switzerland to Delaware via a redomiciliation transaction. The transaction requires shareholder approval and is expected to close by June 30, 2027, with no change in business, capitalization, or shareholder economic interest. The filing is a routine corporate restructuring with no material financial impact.
- Board unanimously approved redomiciliation from Switzerland to Delaware under name ADC Therapeutics, Inc.
- Each issued Swiss common share (CHF 0.08 par value) will convert 1:1 into Delaware common stock ($0.10 par value).
- No dilution; outstanding share count unchanged post-transaction.
- Transaction conditioned on shareholder approval, SEC effectiveness, NYSE listing, Swiss tax rulings, and creditor protections.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access